Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGAVE-256 pediatric axatilimab versus best available therapy in chronic graft-versus-host disease
2025-521849-25-00Phase 2Authorised
- Sponsor
- Incyte
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of axatilimab in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Incyte. Primary endpoint: Overall response at 6 months. Planned start Feb 2026; status: authorised.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2025-521849-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521849-25-00.